Scott Bizily - Mar 27, 2024 Form 4 Insider Report for 4D Molecular Therapeutics, Inc. (FDMT)

Role
Chief Legal Officer
Signature
By: /s/ Scott Bizily
Stock symbol
FDMT
Transactions as of
Mar 27, 2024
Transactions value $
-$52,869
Form type
4
Date filed
3/29/2024, 04:52 PM
Previous filing
Mar 20, 2024
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FDMT Common Stock Options Exercise $113K +4.34K +249.97% $25.98 6.08K Mar 27, 2024 Direct F1
transaction FDMT Common Stock Options Exercise $38.7K +1.49K +24.53% $25.98 7.57K Mar 27, 2024 Direct F1
transaction FDMT Common Stock Sale -$204K -5.83K -77.05% $35.04 1.74K Mar 27, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FDMT Stock Option (Right To Buy) Options Exercise $0 -4.34K -7.24% $0.00 55.7K Mar 27, 2024 Common Stock 4.34K $25.98 Direct F1, F3
transaction FDMT Stock Option (Right To Buy) Options Exercise $0 -1.49K -2.68% $0.00 54.2K Mar 27, 2024 Common Stock 1.49K $25.98 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.
F2 The transaction was executed in multiple trades in prices ranging from $35.00 to $35.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.